Shopping Cart
- Remove All
Your shopping cart is currently empty
RP-6306
🥰Excellent
Catalog No. T60889Cas No. 2719793-90-3
Alias (S)-RP-6306
Lunresertib (RP-6306) is a potent, selective, and orally active PKMYT1 inhibitor with an IC50 of 14 nM. Lunresertib (RP-6306) inhibits the growth of CCNE1-amplified tumor cells in several preclinical xenograft models.
RP-6306
🥰Excellent
Purity: 99.28%
Catalog No. T60889Alias (S)-RP-6306Cas No. 2719793-90-3
Lunresertib (RP-6306) is a potent, selective, and orally active PKMYT1 inhibitor with an IC50 of 14 nM. Lunresertib (RP-6306) inhibits the growth of CCNE1-amplified tumor cells in several preclinical xenograft models.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $133 | In Stock | |
| 5 mg | $329 | In Stock | |
| 10 mg | $488 | In Stock | |
| 25 mg | $786 | In Stock | |
| 50 mg | $1,090 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $587 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "RP-6306"
Adavosertib
Cited
MK-1775, AZD1775, Adavosertib (MK-1775)
T2077955365-80-7
Adavosertib (MK-1775) is a small molecule inhibitor of the checkpoint kinase WEE1 (IC50: 5.2 nM). It hinders the G2 DNA damage checkpoint.
- $40
Size
QTY
CitedPD0166285
PD-166285
T6931185039-89-8
PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations.PD0166285 is a novel G2 checkpoint abrogator.
- $52
Size
QTY
ZNL 02-096
Pomalidomide-C3-adavosertib
T411632414418-49-6In house
ZNL 02-096 (Pomalidomide-C3-adavosertib) is a rapid and selective degrader of Wee1 (IC50=3.58 nM).ZNL 02-096 selectively degrades Wee1 at submolar concentrations without damaging PLK1, a secondary target of AZD 1775.ZNL 02-096 induces degradation of Wee1 and accumulation of DNA damage in MOLT-4 cells in vitro, In vitro in MOLT-4 cells, ZNL 02-096 induced Wee1 degradation, accumulation of DNA damage, cell cycle arrest in G2/M phase and apoptosis.ZNL 02-096 showed anti-proliferative effects in 300 cancer cell lines.
- $263
Size
QTY
WEE1-IN-3
JUN76288
T89162272976-28-8
WEE1-IN-3 (JUN76288) is a potent Wee1 kinase inhibitor with an IC50 of <10 nM. It treatment of cancer and other proliferative diseases.
- $64
Size
QTY
Debio-0123
WEE1-IN-5
T98642243882-74-6
Debio-0123 (WEE1-IN-5) is a potent, orally available and highly specific WEE1 inhibitor with an IC 50 in the low nanomolar range. Debio-0123 inhibits phospho-CDC2 which translated into an increase in DNA damage and premature entry into mitosis. Debio-0123 increases the antitumoral activity of Carboplatin in vivo whereas neither agent was active alone [1].
- $96
Size
QTY
PD173952
PD-173952, PD 173952
T24602305820-75-1
PD173952 is a tyrosine (Src) kinase and Myt1 inhibitor with antitumor activity, inhibits Lyn, Abl and Csk, and induces Bcr-Abl-dependent hematopoietic cell apoptosis.
- $98
Size
QTY
PD 407824
PD-407824
T16446622864-54-4
PD 407824 is a chemical BMP sensitiser that promotes increased cellular sensitivity to subthreshold amounts of BMP4.PD 407824 is a potent inhibitor of the checkpoint kinases Chk1 and WEE1 (IC50s: 47 and 97 nM, respectively).
- $69
Size
QTY
PKMYT1-IN-3
T200211
PKMYT1-IN-3 (compound 8ma) is a potent, selective inhibitor of PKMYT1, demonstrating an IC50 of 16.5 nM and exhibiting antitumor activity.
- Inquiry Price
Size
QTY
WEE1-IN-11
T2009242975172-98-4
WEE1-IN-11 (Compound 13) serves as a potent CDK2 inhibitor with an IC50 of 2.0 nM. It exhibits inhibitory effects on several cell lines, including NCI-H446, A427, OVCAR3, C33A, and WiDr, with respective IC50 values of 93.9, 34.5, 86.7, 23.1, and 85 nM.
- Inquiry Price
Size
QTY
PKMYT1-IN-4
T201136
PKMYT1-IN-4 (compound 27) functions as a PKMYT1 inhibitor with an IC50 value under 50 nM.
- Inquiry Price
Size
QTY
Select Batch
Purity:99.28%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Lunresertib (RP-6306) is a potent, selective, and orally active PKMYT1 inhibitor with an IC50 of 14 nM. Lunresertib (RP-6306) inhibits the growth of CCNE1-amplified tumor cells in several preclinical xenograft models. |
| Targets&IC50 | PKMYT1:14 nM |
| In vitro | METHODS: HCC1569 breast cancer cell line was treated with lunresertib (RP-6306) (63, 125, 250, 500 nM) to assess whether PKMYT1 inhibition leads to DNA damage in CCNE1-high cells by monitoring γH2AX levels using quantitative image-based flow cytometry. RESULTS Treatment with lunresertib (RP-6306) induced pan-γH2AX in the HCC1569 breast cancer cell line, suggesting that tumor-derived CCNE1 amplification also renders cells susceptible to DNA damage induction following PKMYT1 inhibition. [1] |
| In vivo | METHODS: lunresertib (RP-6306) (3, 10 and 60 mg/kg, oral, daily) was used to treat CCNE1-amplified ovary xenograft model (OVCAR3) mice, and tumor growth in the mice was observed. RESULTS lunresertib (RP-6306) inhibited tumor growth in OVCAR3 mice in a statistically significant concentration-dependent manner. [2] |
| Alias | (S)-RP-6306 |
| Molecular Weight | 324.38 |
| Formula | C18H20N4O2 |
| Cas No. | 2719793-90-3 |
| Smiles | NC=1N(C=2C(C1C(N)=O)=CC(C)=C(C)N2)C3=C(C)C(O)=CC=C3C |
Storage & Solubility Information
| Storage | keep away from direct sunlight,keep away from moisture,store at low temperature | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45.0 mg/mL (138.7 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy RP-6306 | purchase RP-6306 | RP-6306 cost | order RP-6306 | RP-6306 chemical structure | RP-6306 in vivo | RP-6306 in vitro | RP-6306 formula | RP-6306 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.